RecruitingNot ApplicableNCT04819737

Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences

Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences: A Pilot Study


Sponsor

University Hospital, Basel, Switzerland

Enrollment

10 participants

Start Date

Jul 18, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis (MS) lesion detection and to evaluate the additional clinical value of this sequence in clinical settings.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing new types of MRI scans to better detect damage to the spinal cord in people with multiple sclerosis (MS). Spinal cord lesions can be hard to see with standard MRI, so researchers are trialing advanced imaging sequences to improve detection accuracy. **You may be eligible if...** - You have been diagnosed with multiple sclerosis according to established clinical criteria - You have not taken steroids for at least 4 weeks before the study - You are already participating in the Swiss MS Cohort study **You may NOT be eligible if...** - You have another serious neurological, internal, or psychiatric illness affecting the spinal cord - You have a pacemaker or metal implants in your body that are not MRI-safe - You have claustrophobia (fear of enclosed spaces) - You are pregnant or breastfeeding - You have a known allergy to gadolinium contrast dye used in MRI Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESC MRI

SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.

OTHERpatient questionnaire

12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability


Locations(1)

University Hospital Basel, Department of Neurology

Basel, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04819737


Related Trials